AD
Conditions
Keywords
Scopolamine, AD, EEG, MCI
Brief summary
The objective of this study is to compare the electroencephalography (EEG) responses of three distinct groups of individuals to scopolamine: 1) a group of Alzheimer Dementia (AD) patients, 2) a group of individuals suffering from Mild Cognitive Impairment (MCI) and 3) a group of controls. The main purpose of this comparison is to discover ways to use these responses to distinguish between the group of AD patients and controls in order to develop a diagnostic tool for AD. The purpose of including the MCI group is to investigate whether this diagnostic tool can predict which member of the MCI group will develop AD later in life.
Interventions
DRUGScopolamine
0.3 mg/mL, intravenously, once
Sponsors
Landspitali University Hospital
Mentis Cura
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
60 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
Healthy subjects: * Between 60-80 years of age. * Volunteers will have to be in good general health as determined by standard physical examination. * Normal Electrocardiograph (ECG) MCI subjects: * Diagnosed with MCI at the Memory Clinic at the Landspitali University Hospital using F 06,7 according to International Classification of Diseases (ICD) - 10. * Between 60-80 years of age. * Subjects need to score between 2 and 3 on the Global Deterioration Scale (GDS). * Normal ECG Alzheimer's patients: * Diagnosed with AD according to ICD - 10 in Follow up at the Memory Clinic at the Landspitali University Hospital. * Between 60-80 years of age. * Subjects need to score between 3-5 on the GDS. * Normal ECG * Treated with Reminyl® for the Alzheimer disease.
Exclusion criteria
* Smoking or any other use of tobacco. * Taking neuroleptics or benzodiazepines (allowed to take oxazepam ad vesp). * Neurological-, cardiovascular-, gastrointestinal- or genitourinary disorders of medical importance. * Glaucoma or history of possibly raised intraocular pressure. * Impaired liver- or kidney function. * Hypersensitivity to Scopolamine or any component in the formulation. * Any indication of drug, alcohol or medicine abuse. * Participation in another investigational study at the same time.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in EEG as a result of scopolamine administration | 1 hr after scopolamine administration | The EEG is recorded before, during and after scopolamine administration in order to monitor the effects scopolamine has on the brain as measured by EEG. |
Outcome results
None listed